View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
August 17, 2021

Rocket Pharma to resume enrolment in Danon disease trial

The trial was put on clinical hold by FDA in May 2021 to amend its protocol and other supporting documents.

Rocket Pharmaceuticals is set to resume participant enrolment in its Phase I clinical trial of RP-A501 to treat Danon disease, after the US Food and Drug Administration (FDA) lifted the trial’s clinical hold.

The FDA decision comes after the company addressed the agency’s requests to change the trial protocol and other supporting documents with updated subject selection and management guidelines.

Rocket Pharma is currently working to restart the programme soon and anticipates beginning dosing in the 6.7e13vg/kg low-dose paediatric patient cohort in the third quarter of this year.

Long-term results from the low-dose and 1.1e14vg/kg higher-dose young adult cohorts are expected in the fourth quarter.

Rocket Pharmaceuticals CEO Gaurav Shah said: “We are moving as quickly as possible to resume dosing and commence treatment this quarter.

“Additionally, given the activity observed among young adults in our low-dose cohort, in agreement with the FDA, we are now proceeding with the paediatric cohort.”

Danon disease is a rare inherited condition that develops due to mutations in the gene encoding lysosome-associated membrane protein 2 (LAMP-2). The disorder can result in heart failure and even death.

RP-A501 is an experimental gene therapy being developed to treat Danon disease and the first gene therapy with the potential to treat monogenic heart failure.

The therapeutic contains a recombinant adeno-associated serotype 9 (AAV9) capsid with a functional form of the human LAMP2B transgene (AAV9.LAMP2B).

FDA placed RP-A501’s Danon disease programme on clinical hold in May 2021 to alter the trial protocol and other supporting documents.

As part of or during the hold, no new safety events associated with the gene therapy were reported in the low-dose or higher-dose young adult cohorts.

The non-randomised, open-label Phase I trial is intended to recruit paediatric and young adult male patients to evaluate the safety and tolerability of RP-A501’s single intravenous infusion.

Other outcome measures in the trial include cardiomyocyte and skeletal muscle transduction by gene expression and histologic correction using endomyocardial biopsy.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU